0001209191-20-004742.txt : 20200123
0001209191-20-004742.hdr.sgml : 20200123
20200123192821
ACCESSION NUMBER: 0001209191-20-004742
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200121
FILED AS OF DATE: 20200123
DATE AS OF CHANGE: 20200123
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Horn Patrick Taylor
CENTRAL INDEX KEY: 0001572002
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33451
FILM NUMBER: 20543435
MAIL ADDRESS:
STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC.
STREET 2: 480 ARSENAL STREET, SUITE 110
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALBIREO PHARMA, INC.
CENTRAL INDEX KEY: 0001322505
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 POST OFFICE SQUARE
STREET 2: SUITE 502 SOUTH
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: 857-415-4774
MAIL ADDRESS:
STREET 1: 10 POST OFFICE SQUARE
STREET 2: SUITE 502 SOUTH
CITY: BOSTON
STATE: MA
ZIP: 02109
FORMER COMPANY:
FORMER CONFORMED NAME: Biodel Inc
DATE OF NAME CHANGE: 20050331
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-21
0
0001322505
ALBIREO PHARMA, INC.
ALBO
0001572002
Horn Patrick Taylor
C/O ALBIREO PHARMA, INC.
10 POST OFFICE SQUARE, SUITE 1000
BOSTON
MA
02109
0
1
0
0
Chief Medical Officer
Common Stock
2020-01-22
4
S
0
443
24.29
D
4557
D
Stock Option (right to buy)
24.67
2020-01-21
4
A
0
31500
0.00
A
2030-01-20
Common Stock
31500
31500
D
Shares sold pursuant to a Rule 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Represents 807 shares of common stock and 3,750 restricted stock units.
This option vests as to 25% of the shares on January 21, 2021, with the remainder vesting in equal installments every three months thereafter beginning on April 21, 2021 and ending on January 21, 2024, provided that the vesting of the option may be accelerated, in whole or in part, based on the achievement of certain pre-established company performance criteria, but in no event prior to January 21, 2021.
/s/ Jason Duncan, Attorney-in-fact
2020-01-23